findmyKOL

Donald Bodenner, MD

Basic profile

University of Arkansas for Medical Sciences

ORCIDNone on fileNPI
RegionLittle Rock, AR · South CentralSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2006findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH funding1997–2006Why? →

Donald Bodenner is an Endocrinology/Metabolic physician affiliated with University of Arkansas for Medical Sciences. OpenAlex indexes 89 publications with 4,047 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
89publications

Distinct works indexed by OpenAlex.

4,047citations

Total citations across indexed works.

30h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
2NIH grants · 1997–2006

Federally funded research awards.

View funding

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    43.8%
    l-Thyroxine32.3%
    Levothyroxine Sodium82%Synthroid18%
    Part D86 patients
    Thyroid Hormone Synthesis Inhibitor10.2%
    Methimazole100%
    Part D23 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    32.6%
    Biguanide (metformin)7.3%
    Metformin Hcl75%Metformin Hcl Er25%
    Part D<11 patients
    Insulin Analog6.8%
    Lantus Solostar40%Toujeo Solostar22%Basaglar Kwikpen U-10019%Levemir Flexpen19%
    Part D<11 patients

    + 8 more classes in this area

  • Cardiovascular

    12.9%
    Statin6.3%
    Atorvastatin Calcium64%Pravastatin Sodium36%
    Part D<11 patients
    Calcium channel blocker2.6%
    Amlodipine Besylate100%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 19972006 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”